论文部分内容阅读
目的观察香菇多糖联合化疗治疗晚期非小细胞肺癌(NSCLC)的疗效。方法92例晚期NSCLC患者随机分为治疗组和对照组,治疗组采用香菇多糖加化疗,对照组采用单纯化疗。两组患者在治疗前后测定外周血T淋巴细胞亚群和NK细胞活性,对患者疗效、免疫功能、生活质量及不良反应进行评价。结果治疗组的有效率为61.7%,明显高于对照组的40%,差异有统计学意义(P<0.05);治疗组的T淋巴细胞亚群和NK细胞活性明显高于对照组,差异有统计学意义(P<0.05),免疫功能明显改善;治疗组的Karnofsky评分上升率(53.2%)高于对照组(26.6%),差异有统计学意义(P<0.05)。结论香菇多糖联合化疗治疗晚期NSCLC的疗效优于单纯化疗。
Objective To observe the efficacy of lentinan combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 92 patients with advanced NSCLC were randomly divided into treatment group and control group. The treatment group was treated with lentinan plus chemotherapy. The control group was treated with chemotherapy alone. The T lymphocyte subsets and NK cell activity in peripheral blood were measured before and after treatment in both groups, and the efficacy, immune function, quality of life, and adverse reactions were evaluated. Results The effective rate in the treatment group was 61.7%, which was significantly higher than 40% in the control group (P<0.05). The T lymphocyte subsets and NK cell activity in the treatment group were significantly higher than those in the control group. Statistical significance (P<0.05), immune function improved significantly; the Karnofsky score increase rate in the treatment group (53.2%) was higher than the control group (26.6%), the difference was statistically significant (P<0.05). Conclusion The efficacy of lentinan combined with chemotherapy in the treatment of advanced NSCLC is superior to chemotherapy alone.